{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:34:20Z","timestamp":1771364060235,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12664-024-01537-x","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:02:26Z","timestamp":1708416146000},"page":"145-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antibiotics for inflammatory bowel disease: Current status"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-0314","authenticated-orcid":false,"given":"Daya K.","family":"Jha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-9760","authenticated-orcid":false,"given":"Shubhra","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-3557","authenticated-orcid":false,"given":"Usha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-3409","authenticated-orcid":false,"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S2468-1253(21)00336-8","volume":"6","author":"T Aswani-Omprakash","year":"2021","unstructured":"Aswani-Omprakash T, Sharma V, Bishu S, et al. Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance. Lancet Gastroenterol Hepatol. 2021;6:884\u20135.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1537_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6:22.","journal-title":"Nat Rev Dis Primers."},{"key":"1537_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3748\/wjg.v24.i1.5","volume":"24","author":"ZH Shen","year":"2018","unstructured":"Shen ZH, Zhu CX, Quan YS, et al. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24:5\u201314.","journal-title":"World J Gastroenterol."},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nmicrobiol.2017.4","volume":"2","author":"J Halfvarson","year":"2017","unstructured":"Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004.","journal-title":"Nat Microbiol."},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.coph.2010.05.007","volume":"10","author":"A Mizoguchi","year":"2010","unstructured":"Mizoguchi A, Mizoguchi E. Animal models of IBD: linkage to human disease. Curr Opin Pharmacol. 2010;10:578\u201387.","journal-title":"Curr Opin Pharmacol."},{"key":"1537_CR6","doi-asserted-by":"crossref","unstructured":"Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22:1078\u201387.","DOI":"10.3748\/wjg.v22.i3.1078"},{"key":"1537_CR7","doi-asserted-by":"crossref","unstructured":"Singh A, Mahajan R, Kahlon BK, et al. Early fecal microbiome transfer after donor defecation determines response in patients with moderate to severe ulcerative colitis. Indian J Gastroenterol. 2022;41:389\u201396.","DOI":"10.1007\/s12664-022-01257-0"},{"key":"1537_CR8","unstructured":"Labro MT. Antibiotics as anti-inflammatory agents. Curr Opin Investig Drugs. 2002;3:61\u20138."},{"key":"1537_CR9","doi-asserted-by":"crossref","unstructured":"Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775\u20138.","DOI":"10.1097\/01.meg.0000131040.38607.09"},{"key":"1537_CR10","doi-asserted-by":"crossref","unstructured":"Axelrad JE, Joelson A, Green PHR, et al. Enteric infections are common in patients with flares of inflammatory bowel disease. Am J Gastroenterol. 2018;113:1530\u20139.","DOI":"10.1038\/s41395-018-0211-8"},{"key":"1537_CR11","doi-asserted-by":"crossref","unstructured":"Navarro-Llavat M, Dom\u00e8nech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009;80:25\u20139.","DOI":"10.1159\/000212076"},{"key":"1537_CR12","doi-asserted-by":"crossref","unstructured":"Yamamoto-Furusho JK, Torijano-Carrera E. Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course. Digestion. 2010;82:18\u201323.","DOI":"10.1159\/000273871"},{"key":"1537_CR13","doi-asserted-by":"crossref","unstructured":"Banerjee D, Deb R, Dar L, et al. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44:325\u201331.","DOI":"10.1080\/00365520802556809"},{"key":"1537_CR14","doi-asserted-by":"crossref","unstructured":"Hokama A, Tomiyama R. Ulcerative colitis exacerbated by strongyloidiasis. Rev Esp Enferm Dig. 2023;115:102\u20133.","DOI":"10.17235\/reed.2022.9088\/2022"},{"key":"1537_CR15","doi-asserted-by":"crossref","unstructured":"Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15:879\u2013913.","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"1537_CR16","doi-asserted-by":"crossref","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041\u20138.","DOI":"10.1136\/bmj.2.4947.1041"},{"key":"1537_CR17","doi-asserted-by":"crossref","unstructured":"Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27:1210\u20132.","DOI":"10.1136\/gut.27.10.1210"},{"key":"1537_CR18","unstructured":"Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994;89:43\u20136."},{"key":"1537_CR19","doi-asserted-by":"publisher","unstructured":"Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001;36:971\u20134. https:\/\/doi.org\/10.1080\/003655201750305503.","DOI":"10.1080\/003655201750305503"},{"key":"1537_CR20","doi-asserted-by":"crossref","unstructured":"Mishra S, Mandavdhare HS, Singh H, et al. Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: a placebo controlled randomized trial. Expert Rev Anti Infect Ther. 2021;19:949\u201355.","DOI":"10.1080\/14787210.2021.1856656"},{"key":"1537_CR21","doi-asserted-by":"crossref","unstructured":"Turner D, Bishai J, Reshef L, et al. Antibiotic cocktail for pediatric acute severe colitis and the microbiome: the PRASCO randomized controlled trial. Inflamm Bowel Dis. 2020;26:1733\u201342.","DOI":"10.1093\/ibd\/izz298"},{"key":"1537_CR22","doi-asserted-by":"crossref","unstructured":"Mishra S, Jha DK, Singh AK, Kumar-M P, Patil A, Sharma V. Antibiotics for induction and maintenance of remission in ulcerative colitis: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15:1215\u201323.","DOI":"10.1080\/17474124.2021.1914586"},{"key":"1537_CR23","doi-asserted-by":"crossref","unstructured":"Dickinson RJ, O\u2019Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26:1380\u20134.","DOI":"10.1136\/gut.26.12.1380"},{"key":"1537_CR24","doi-asserted-by":"crossref","unstructured":"Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990;4:123\u20139.","DOI":"10.1111\/j.1365-2036.1990.tb00456.x"},{"key":"1537_CR25","doi-asserted-by":"crossref","unstructured":"Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44:1220\u20131.","DOI":"10.1023\/A:1026648812439"},{"key":"1537_CR26","doi-asserted-by":"crossref","unstructured":"Casellas F, Borruel N, Papo M, et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis. 1998;4:1\u20135.","DOI":"10.1097\/00054725-199802000-00001"},{"key":"1537_CR27","unstructured":"Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997;92:454\u20136."},{"key":"1537_CR28","doi-asserted-by":"crossref","unstructured":"Petersen AM, Mirsepasi H, Halkj\u00e6r SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis. 2014;8:1498\u2013505.","DOI":"10.1016\/j.crohns.2014.06.001"},{"key":"1537_CR29","doi-asserted-by":"crossref","unstructured":"Gilat T, Suissa A, Leichtman G, et al. A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol. 1987;9:415\u20137.","DOI":"10.1097\/00004836-198708000-00011"},{"key":"1537_CR30","doi-asserted-by":"crossref","unstructured":"Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol. 2005;40:1334\u201342.","DOI":"10.1080\/00365520510023648"},{"key":"1537_CR31","doi-asserted-by":"crossref","unstructured":"Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820\u20139.","DOI":"10.1038\/ajg.2010.84"},{"key":"1537_CR32","doi-asserted-by":"crossref","unstructured":"Turunen UM, F\u00e4rkkil\u00e4 MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115:1072\u20138.","DOI":"10.1016\/S0016-5085(98)70076-9"},{"key":"1537_CR33","doi-asserted-by":"crossref","unstructured":"Gilat T, Leichtman G, Delpre G, Eshchar J, Bar Meir S, Fireman Z. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol. 1989;11:392\u20135.","DOI":"10.1097\/00004836-198908000-00008"},{"key":"1537_CR34","doi-asserted-by":"crossref","unstructured":"Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther. 1993;7:155\u20138.","DOI":"10.1111\/j.1365-2036.1993.tb00084.x"},{"key":"1537_CR35","doi-asserted-by":"crossref","unstructured":"Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52:79\u201383.","DOI":"10.1136\/gut.52.1.79"},{"key":"1537_CR36","doi-asserted-by":"crossref","unstructured":"Gupta V, Rodrigues R, Nguyen D, et al. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. Aliment Pharmacol Ther. 2016;43:52\u201360.","DOI":"10.1111\/apt.13454"},{"key":"1537_CR37","doi-asserted-by":"crossref","unstructured":"Bernstein CN, Eliakim A, Fedail S, et al. World Gastroenterology Organisation Global Guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol. 2016;50:803\u201318.","DOI":"10.1097\/MCG.0000000000000660"},{"key":"1537_CR38","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [published correction appears in Gut. 2021 ;70:1].\u00a0 Gut. 2019;68 Suppl 3:s1\u2013106."},{"key":"1537_CR39","doi-asserted-by":"crossref","unstructured":"Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14:4\u201322.","DOI":"10.1093\/ecco-jcc\/jjaa043"},{"key":"1537_CR40","doi-asserted-by":"crossref","unstructured":"Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn\u2019s disease. World J Gastroenterol. 2013;19:648\u201353.","DOI":"10.3748\/wjg.v19.i5.648"},{"key":"1537_CR41","doi-asserted-by":"crossref","unstructured":"Choudhury A, Dhillon J, Sekar A, Gupta P, Singh H, Sharma V. Differentiating gastrointestinal tuberculosis and Crohn\u2019s disease- a comprehensive review. BMC Gastroenterol. 2023;23:246.","DOI":"10.1186\/s12876-023-02887-0"},{"key":"1537_CR42","doi-asserted-by":"crossref","unstructured":"Townsend CM, Parker CE, MacDonald JK, et al. Antibiotics for induction and maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2019;2:CD012730.","DOI":"10.1002\/14651858.CD012730.pub2"},{"key":"1537_CR43","doi-asserted-by":"crossref","unstructured":"Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn\u2019s disease. A double blind cross-over clinical trial. Scand J Gastroenterol. 1978;13:123\u20137.","DOI":"10.3109\/00365527809179816"},{"key":"1537_CR44","doi-asserted-by":"crossref","unstructured":"Sutherland L, Singleton J, Sessions J, et al. Double-blind, placebo-controlled trial of metronidazole in Crohn\u2019s disease. Gut. 1991;32:1071\u20135.","DOI":"10.1136\/gut.32.9.1071"},{"key":"1537_CR45","doi-asserted-by":"crossref","unstructured":"Ursing B, Alm T, B\u00e1r\u00e1ny F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn\u2019s disease: the cooperative Crohn\u2019s disease study in Sweden II. Result. Gastroenterology. 1982;83:550\u201362.","DOI":"10.1016\/S0016-5085(82)80189-3"},{"key":"1537_CR46","doi-asserted-by":"crossref","unstructured":"Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn\u2019s disease. Inflamm Bowel Dis. 2002;8:10\u20135.","DOI":"10.1097\/00054725-200201000-00002"},{"key":"1537_CR47","doi-asserted-by":"crossref","unstructured":"Colombel JF, L\u00e9mann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn\u2019s disease. Groupe d\u2019Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94:674\u20138.","DOI":"10.1111\/j.1572-0241.1999.935_q.x"},{"key":"1537_CR48","doi-asserted-by":"crossref","unstructured":"Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn\u2019s disease: a randomized controlled trial. Gastroenterology. 2002;123:33\u201340.","DOI":"10.1053\/gast.2002.34225"},{"key":"1537_CR49","unstructured":"Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn\u2019s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328\u201332."},{"key":"1537_CR50","doi-asserted-by":"crossref","unstructured":"Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn\u2019s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23:1117\u201325.","DOI":"10.1111\/j.1365-2036.2006.02879.x"},{"key":"1537_CR51","doi-asserted-by":"crossref","unstructured":"Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease. Gastroenterology. 2012;142:473\u201381.","DOI":"10.1053\/j.gastro.2011.11.032"},{"key":"1537_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ygh2.416","volume":"2","author":"SD Lee","year":"2020","unstructured":"Lee SD, Singla A, Rulyak SJ, Clark-Snustad K. Double-blind, randomised, placebo-controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn\u2019s disease. GastroHep. 2020;2:185\u201392.","journal-title":"GastroHep."},{"key":"1537_CR53","doi-asserted-by":"crossref","unstructured":"Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22:1078\u201387.","DOI":"10.3748\/wjg.v22.i3.1078"},{"key":"1537_CR54","doi-asserted-by":"crossref","unstructured":"Ambrose NS, Allan RN, Keighley MR, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn\u2019s disease. A prospective randomized study. Dis Colon Rectum. 1985;28(2):81\u20135.","DOI":"10.1007\/BF02552649"},{"key":"1537_CR55","doi-asserted-by":"crossref","unstructured":"Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;27:1233\u20139.","DOI":"10.1111\/j.1365-2036.2008.03661.x"},{"key":"1537_CR56","doi-asserted-by":"crossref","unstructured":"Rhodes JM, Subramanian S, Flanagan PK, et al. Randomized trial of ciprofloxacin doxycycline and hydroxychloroquine versus budesonide in active Crohn\u2019s disease. Dig Dis Sci. 2021;66:2700\u201311.","DOI":"10.1007\/s10620-020-06477-y"},{"key":"1537_CR57","doi-asserted-by":"crossref","unstructured":"Pan\u00e9s J, Rimola J. Perianal fistulizing Crohn\u2019s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652\u201364.","DOI":"10.1038\/nrgastro.2017.104"},{"key":"1537_CR58","doi-asserted-by":"crossref","unstructured":"Wetwittayakhlang P, Al Khoury A, Hahn GD, Lakatos PL. The optimal management of fistulizing Crohn\u2019s disease: evidence beyond randomized clinical trials. J Clin Med. 2022;11:3045.","DOI":"10.3390\/jcm11113045"},{"key":"1537_CR59","doi-asserted-by":"crossref","unstructured":"Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn\u2019s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15:17\u201324.","DOI":"10.1002\/ibd.20608"},{"key":"1537_CR60","doi-asserted-by":"crossref","unstructured":"Maeda Y, Ng SC, Durdey P, et al. Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn\u2019s disease. Br J Surg. 2010;97:1340\u20137.","DOI":"10.1002\/bjs.7121"},{"key":"1537_CR61","doi-asserted-by":"crossref","unstructured":"Su JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn\u2019s disease: a systematic review and meta-analysis. J Dig Dis. 2015;16:58\u201366.","DOI":"10.1111\/1751-2980.12216"},{"key":"1537_CR62","doi-asserted-by":"crossref","unstructured":"West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn\u2019s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329\u201336.","DOI":"10.1111\/j.1365-2036.2004.02247.x"},{"key":"1537_CR63","doi-asserted-by":"crossref","unstructured":"Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292\u20139.","DOI":"10.1136\/gutjnl-2013-304488"},{"key":"1537_CR64","doi-asserted-by":"crossref","unstructured":"Richards RJ. Management of abdominal and pelvic abscess in Crohn\u2019s disease. World J Gastrointest Endosc. 2011;3:209\u201312.","DOI":"10.4253\/wjge.v3.i11.209"},{"key":"1537_CR65","doi-asserted-by":"crossref","unstructured":"Clancy C, Boland T, Deasy J, McNamara D, Burke JP. A meta-analysis of percutaneous drainage versus surgery as the initial treatment of Crohn\u2019s disease-related intra-abdominal abscess. J Crohns Colitis. 2016;10:202\u20138.","DOI":"10.1093\/ecco-jcc\/jjv198"},{"key":"1537_CR66","doi-asserted-by":"crossref","unstructured":"Feagins LA, Holubar SD, Kane SV, Spechler SJ. Current strategies in the management of intra-abdominal abscesses in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2011;9:842\u201350.","DOI":"10.1016\/j.cgh.2011.04.023"},{"key":"1537_CR67","doi-asserted-by":"crossref","unstructured":"De Groof EJ, Carbonnel F, Buskens CJ, Bemelman WA. Abdominal abscess in Crohn\u2019s disease: multidisciplinary management. Dig Dis. 2014;32 Suppl 1:103\u20139.","DOI":"10.1159\/000367859"},{"key":"1537_CR68","doi-asserted-by":"crossref","unstructured":"Vuitton L, Peyrin-Biroulet L. Pharmacological prevention of postoperative recurrence in Crohn\u2019s disease. Drugs. 2020;80:385\u201399.","DOI":"10.1007\/s40265-020-01266-3"},{"key":"1537_CR69","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn\u2019s recurrence after ileal resection. Gastroenterology. 1995;108:1617\u201321.","DOI":"10.1016\/0016-5085(95)90121-3"},{"key":"1537_CR70","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn\u2019s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128:856\u201361.","DOI":"10.1053\/j.gastro.2005.01.010"},{"key":"1537_CR71","doi-asserted-by":"crossref","unstructured":"Herfarth HH, Katz JA, Hanauer SB, et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn\u2019s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013;19:1073\u20139.","DOI":"10.1097\/01.MIB.0000428910.36091.10"},{"key":"1537_CR72","doi-asserted-by":"crossref","unstructured":"Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet. 1978;2\u00a0 Pt 1:693\u20136.","DOI":"10.1016\/S0140-6736(78)92699-5"},{"key":"1537_CR73","doi-asserted-by":"crossref","unstructured":"Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn\u2019s disease tissue. Gut. 1992;33:890\u20136.","DOI":"10.1136\/gut.33.7.890"},{"key":"1537_CR74","doi-asserted-by":"crossref","unstructured":"Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn\u2019s disease. Am J Gastroenterol. 2000;95:725\u20139.","DOI":"10.1111\/j.1572-0241.2000.01842.x"},{"key":"1537_CR75","doi-asserted-by":"crossref","unstructured":"Patton PH, Parker CE, MacDonald JK, Chande N. Anti-tuberculous therapy for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016;7:CD000299.","DOI":"10.1002\/14651858.CD000299.pub3"},{"key":"1537_CR76","doi-asserted-by":"crossref","unstructured":"Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn\u2019s disease. Gastroenterology. 2007;132:2313\u20139.","DOI":"10.1053\/j.gastro.2007.03.031"},{"key":"1537_CR77","doi-asserted-by":"crossref","unstructured":"Goodgame RW, Kimball K, Akram S, et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther. 2001;15:1861\u20136.","DOI":"10.1046\/j.1365-2036.2001.01099.x"},{"key":"1537_CR78","doi-asserted-by":"crossref","unstructured":"Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn\u2019s disease. Gut. 1994;35:363\u20138.","DOI":"10.1136\/gut.35.3.363"},{"key":"1537_CR79","unstructured":"Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn\u2019s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994;89:513\u20138."},{"key":"1537_CR80","doi-asserted-by":"crossref","unstructured":"Afdhal NH, Long A, Lennon J, Crowe J, O\u2019Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn\u2019s disease. Clofazimine versus placebo. Dig Dis Sci. 1991;36:449\u201353.","DOI":"10.1007\/BF01298873"},{"key":"1537_CR81","doi-asserted-by":"crossref","unstructured":"Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA. Controlled trial of rifampicin and ethambutol in Crohn\u2019s disease. Gut. 1984;25:203\u20135.","DOI":"10.1136\/gut.25.2.203"},{"key":"1537_CR82","doi-asserted-by":"crossref","unstructured":"Elliott PR, Burnham WR, Berghouse LM, Lennard-Jones JE, Langman MJ. Sulphadoxine-pyrimethamine therapy in Crohn\u2019s disease. Digestion. 1982;23:132\u20134.","DOI":"10.1159\/000198703"},{"key":"1537_CR83","first-page":"245","volume":"46","author":"G Basilisco","year":"1989","unstructured":"Basilisco G, Ranzi T, Campanini MC, Piodi L, Bianchi PA. Controlled trial of rifabutin in Crohn\u2019s disease. Curr Ther Res. 1989;46:245\u201350.","journal-title":"Curr Ther Res"},{"key":"1537_CR84","doi-asserted-by":"crossref","unstructured":"Graham DY, Naser SA, Offman E, et al. 643 RHB-104, a fixed-dose, oral antibiotic combination against mycobacterium avium paratuberculosis (MAP) infection, is effective in moderately to severely active Crohn\u2019s disease. Am J Gastroenterol. 2019;114:S376\u20137.","DOI":"10.14309\/01.ajg.0000592108.53051.68"},{"key":"1537_CR85","doi-asserted-by":"crossref","unstructured":"Gupta A, Pratap Mouli V, Mohta S, et al. Antitubercular therapy given to differentiate Crohn\u2019s disease from intestinal tuberculosis predisposes to stricture formation. J Crohns Colitis. 2020;14:1611\u20138.","DOI":"10.1093\/ecco-jcc\/jjaa091"},{"key":"1537_CR86","doi-asserted-by":"crossref","unstructured":"Liu F, Tang J, Ye L, et al. Prophylactic antitubercular therapy is associated with accelerated disease progression in patients with Crohn\u2019s disease receiving anti-TNF therapy: a retrospective multicenter study. Clin Transl Gastroenterol. 2022;13:e00493.","DOI":"10.14309\/ctg.0000000000000493"},{"key":"1537_CR87","doi-asserted-by":"crossref","unstructured":"Sharma V, Mandavdhare HS, Lamoria S, Singh H, Kumar A. Serial C-reactive protein measurements in patients treated for suspected abdominal tuberculosis. Dig Liver Dis. 2018;50:559\u201362.","DOI":"10.1016\/j.dld.2017.12.008"},{"key":"1537_CR88","doi-asserted-by":"crossref","unstructured":"Sharma V, Verma S, Kumar-M P, et al. Serial measurements of faecal calprotectin may discriminate intestinal tuberculosis and Crohn\u2019s disease in patients started on antitubercular therapy. Eur J Gastroenterol Hepatol. 2021;33:334\u20138.","DOI":"10.1097\/MEG.0000000000001879"},{"key":"1537_CR89","doi-asserted-by":"crossref","unstructured":"Sharma V, Mandavdhare HS, Dutta U. Letter: Mucosal response in discriminating intestinal tuberculosis from Crohn\u2019s disease-when to look for it?. Aliment Pharmacol Ther. 2018;47:859\u201360.","DOI":"10.1111\/apt.14495"},{"key":"1537_CR90","doi-asserted-by":"crossref","unstructured":"Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn\u2019s disease. Gastroenterology. 1998;115:1405\u201313.","DOI":"10.1016\/S0016-5085(98)70019-8"},{"key":"1537_CR91","doi-asserted-by":"crossref","unstructured":"Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn\u2019s disease. Curr Opin Gastroenterol. 2007;23:16\u201320.","DOI":"10.1097\/MOG.0b013e3280105a38"},{"key":"1537_CR92","doi-asserted-by":"publisher","unstructured":"Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4. https:\/\/doi.org\/10.1128\/microbiolspec.VMBF-0016-2015.","DOI":"10.1128\/microbiolspec.VMBF-0016-2015"},{"key":"1537_CR93","doi-asserted-by":"crossref","unstructured":"Shen B, Kochhar GS, Rubin DT, et al. Treatment of pouchitis, Crohn\u2019s disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022;7:69\u201395.","DOI":"10.1016\/S2468-1253(21)00214-4"},{"key":"1537_CR94","doi-asserted-by":"crossref","unstructured":"Barnes EL, Desai A, Kochhar GS. The comparative effectiveness of ciprofloxacin and metronidazole for an initial episode of pouchitis: a propensity-matched study. Am J Gastroenterol. 2023;118:1989\u201396.","DOI":"10.14309\/ajg.0000000000002412"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01537-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-024-01537-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01537-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T23:10:30Z","timestamp":1709939430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-024-01537-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1007\/s12664-024-01537-x","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DKJ, SM, UD and VS declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members,\u00a0the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/findings and content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}